Company Overview

NeuroSigma, Inc. is a life sciences company founded in and based in Westwood, California. NeuroSigma is focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI). NeuroSigma is actively engaged in innovative preclinical research and development, as well as Phase I, II, & III clinical trials.

Key Milestones

  • In July 2010, we obtained an exclusive, worldwide license to patented and patent-pending technologies relating to transcutaneous and subcutaneous bilateral neurostimulation for the treatment of neuropsychiatric and neurological disorders from the University of California, Los Angeles, (UCLA).

  • In August 2012, we received CE Mark approval in the European Union, or the EU, to market our eTNS system as adjunctive treatment for drug-resistant epilepsy (DRE), and major depressive disorder (MDD), for adults and children nine years and older.

  • In January 2013, the results of the Phase II clinical trial of our eTNS system as adjunctive treatment for DRE were published in the online issue of Neurology, the medical journal of the American Academy of Neurology.

  • In April 2013, we received a medical device license from Health Canada, which allows us to market our eTNS system for the treatment of DRE and MDD for adults and children nine years and older.

  • In June 2013, we commenced commercialization of our eTNS system in the EU and Canada.

  • In December 2013, the U.S. Food and Drug Administration unconditionally approved our Investigational Device Exemption, application, allowing us to commence a pivotal trial of our eTNS system as adjunctive treatment for DRE.

  • In March 2014, we received approval to include our eTNS system in the Australian Register of Therapeutic Goods, which allows us to market our eTNS system as adjunctive treatment for DRE for adults and children nine years and older in Australia.


NSVascular

NSVascular, Inc., a majority-owned subsidiary of NeuroSigma, was established to conduct research and development of stent technology for neurovascular brain aneurysms. A website for NSVascular is under construction.

CAUTION: All NSVascular devices are early-stage investigational devices in pre-clinical development, and have no approval for clinical use in any jurisdiction.

Back to Top